Lorenza Landi, MD

Articles by Lorenza Landi, MD

Choosing Between Targeted Therapies and Addressing Unmet Needs

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

January 5th 2026

Panelists discuss treatment selection, resistance challenges, and future directions in managing BRAF-mutated lung cancer.

Recent Clinical Data in BRAF-Mutated NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

January 5th 2026

Panelists discuss the latest trial results supporting dual-pathway inhibition in BRAF-mutated metastatic lung cancer.

Combination Strategies in BRAF-Mutated NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

December 19th 2025

Panelists discuss combination targeted approaches for managing BRAF-mutated lung cancer and their impact on disease durability.

Treatment Options for BRAF-Mutated Metastatic NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

December 19th 2025

Panelists discuss evolving treatment approaches for BRAF-mutated metastatic lung cancer and their clinical impact.

Role of BRAF Mutations in NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

December 12th 2025

Panelists discuss the biology and clinical implications of BRAF mutations in non–small cell lung cancer (NSCLC).

Patient Profile and Treatment Selection in ALK+ NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

December 12th 2025

Panelists discuss individualized treatment selection based on age, comorbidities, and patient preferences in ALK-positive lung cancer.

Emerging Strategies for ALK+ NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

December 5th 2025

Panelists discuss novel research directions aimed at overcoming resistance and extending survival in ALK-positive lung cancer.

Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

December 5th 2025

Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.

Real-World Data in ALK+ NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

November 26th 2025

Panelists discuss how real-world data complement clinical trials in understanding outcomes for ALK-positive lung cancer.

Using Long-Term Data to Guide ALK+ NSCLC Treatment

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

November 26th 2025

Panelists discuss how mature survival data inform treatment sequencing and maintenance strategies in ALK-positive lung cancer.

Investigational Therapies and Ongoing Trials in ROS1+ NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

November 12th 2025

Panelists discuss ongoing research and investigational strategies aimed at overcoming resistance in ROS1-driven lung cancer.

Use of ROS1-Targeting Agents in Clinical Practice

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

November 12th 2025

Panelists discuss translating clinical trial evidence on ROS1-targeted therapy into real-world patient management.

ALK Alterations and Treatment Options for ALK+ NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

November 5th 2025

Panelists discuss the role of ALK rearrangements in lung cancer and the development of successive generations of targeted inhibitors.

Long-Term Data in ALK+ NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

November 5th 2025

Panelists discuss long-term data demonstrating the durability of response and intracranial protection achieved with modern ALK-targeted therapies.

Spotlight on ROS1-Targeted Therapies in Advanced NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

November 5th 2025

Panelists discuss the molecular and clinical characteristics of ROS1-driven lung cancer and the role of precise molecular testing in guiding targeted therapy.

Treatment Options for ROS1+ Advanced NSCLC

ByStephen Liu, MD,Julia Rotow, MD,Alexander Spira, MD, PhD, FACP,Tejas Patil, MD,Lorenza Landi, MD

November 5th 2025

Panelists discuss first-line treatment strategies for ROS1-positive lung cancer and the factors influencing therapy selection and sequencing.

Latest Updated Articles

ALK Alterations and Treatment Options for ALK+ NSCLC
Published: November 5th 2025 | Updated:
Long-Term Data in ALK+ NSCLC
Published: November 5th 2025 | Updated:

Lorenza Landi, MD

Articles by Lorenza Landi, MD

Choosing Between Targeted Therapies and Addressing Unmet Needs

Recent Clinical Data in BRAF-Mutated NSCLC

Combination Strategies in BRAF-Mutated NSCLC

Treatment Options for BRAF-Mutated Metastatic NSCLC

Role of BRAF Mutations in NSCLC

Patient Profile and Treatment Selection in ALK+ NSCLC

Emerging Strategies for ALK+ NSCLC

Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

Real-World Data in ALK+ NSCLC

Using Long-Term Data to Guide ALK+ NSCLC Treatment

Investigational Therapies and Ongoing Trials in ROS1+ NSCLC

Use of ROS1-Targeting Agents in Clinical Practice

ALK Alterations and Treatment Options for ALK+ NSCLC

Long-Term Data in ALK+ NSCLC

Spotlight on ROS1-Targeted Therapies in Advanced NSCLC

Treatment Options for ROS1+ Advanced NSCLC

Latest Updated Articles

Trending on OncLive

FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

Real-World SEER Data Highlight Age-Related Survival Gap in ICI-Treated Advanced RCC